These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 28337383)

  • 1. Pancreatic cancer screening in different risk individuals with family history of pancreatic cancer-a prospective cohort study in Taiwan.
    Chang MC; Wu CH; Yang SH; Liang PC; Chen BB; Jan IS; Chang YT; Jeng YM
    Am J Cancer Res; 2017; 7(2):357-369. PubMed ID: 28337383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New Screening System Using Forward-Viewing Radial Endoscopic Ultrasound and Magnetic Resonance Imaging for High-Risk Individuals With Familial History of Pancreatic Cancer.
    Ashida R; Ioka T; Takada R; Fukutake N; Ikezawa K; Ohkawa K; Nagata S; Takahashi H
    Front Med (Lausanne); 2022; 9():928182. PubMed ID: 35836949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Statewide Retrospective Review of Familial Pancreatic Cancer in Delaware, and Frequency of Genetic Mutations in Pancreatic Cancer Kindreds.
    Catts ZA; Baig MK; Milewski B; Keywan C; Guarino M; Petrelli N
    Ann Surg Oncol; 2016 May; 23(5):1729-35. PubMed ID: 26727920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hereditary pancreatitis as the premalignant disease: a Japanese case of pancreatic cancer involving the SPINK1 gene mutation N34S.
    Masamune A; Mizutamari H; Kume K; Asakura T; Satoh K; Shimosegawa T
    Pancreas; 2004 Apr; 28(3):305-10. PubMed ID: 15084977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CFTR, SPINK1, PRSS1, and CTRC mutations are not associated with pancreatic cancer in German patients.
    Schubert S; Traub F; Brakensiek K; von Kopylow K; Marohn B; Maelzer M; Gaedcke J; Kreipe H; Stuhrmann M
    Pancreas; 2014 Oct; 43(7):1078-82. PubMed ID: 25003218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Five years of prospective screening of high-risk individuals from families with familial pancreatic cancer.
    Langer P; Kann PH; Fendrich V; Habbe N; Schneider M; Sina M; Slater EP; Heverhagen JT; Gress TM; Rothmund M; Bartsch DK
    Gut; 2009 Oct; 58(10):1410-8. PubMed ID: 19470496
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The yield of first-time endoscopic ultrasonography in screening individuals at a high risk of developing pancreatic cancer.
    Poley JW; Kluijt I; Gouma DJ; Harinck F; Wagner A; Aalfs C; van Eijck CH; Cats A; Kuipers EJ; Nio Y; Fockens P; Bruno MJ
    Am J Gastroenterol; 2009 Sep; 104(9):2175-81. PubMed ID: 19491823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pancreatic cancer screening in high-risk individuals with germline genetic mutations.
    DaVee T; Coronel E; Papafragkakis C; Thaiudom S; Lanke G; Chakinala RC; Nogueras González GM; Bhutani MS; Ross WA; Weston BR; Lee JH
    Gastrointest Endosc; 2018 Jun; 87(6):1443-1450. PubMed ID: 29309780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Absence of PRSS1 mutations and association of SPINK1 trypsin inhibitor mutations in hereditary and non-hereditary chronic pancreatitis.
    Chandak GR; Idris MM; Reddy DN; Mani KR; Bhaskar S; Rao GV; Singh L
    Gut; 2004 May; 53(5):723-8. PubMed ID: 15082592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Results of First-Round of Surveillance in Individuals at High-Risk of Pancreatic Cancer from the AISP (Italian Association for the Study of the Pancreas) Registry.
    Paiella S; Capurso G; Cavestro GM; Butturini G; Pezzilli R; Salvia R; Signoretti M; Crippa S; Carrara S; Frigerio I; Bassi C; Falconi M; Iannicelli E; Giardino A; Mannucci A; Laghi A; Laghi L; Frulloni L; Zerbi A
    Am J Gastroenterol; 2019 Apr; 114(4):665-670. PubMed ID: 30538291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Screening for human cationic trypsinogen (PRSS1) and trypsinogen inhibitor gene (SPINK1) mutations in a Finnish family with hereditary pancreatitis.
    Räty S; Piironen A; Babu M; Pelli H; Sand J; Uotila S; Nordback I; Herzig KH
    Scand J Gastroenterol; 2007 Aug; 42(8):1000-5. PubMed ID: 17613931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic Yield From Screening Asymptomatic Individuals at High Risk for Pancreatic Cancer: A Meta-analysis of Cohort Studies.
    Corral JE; Mareth KF; Riegert-Johnson DL; Das A; Wallace MB
    Clin Gastroenterol Hepatol; 2019 Jan; 17(1):41-53. PubMed ID: 29775792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short-term Results of a Magnetic Resonance Imaging-Based Swedish Screening Program for Individuals at Risk for Pancreatic Cancer.
    Del Chiaro M; Verbeke CS; Kartalis N; Pozzi Mucelli R; Gustafsson P; Hansson J; Haas SL; Segersvärd R; Andren-Sandberg Å; Löhr JM
    JAMA Surg; 2015 Jun; 150(6):512-8. PubMed ID: 25853369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Motion--genetic testing is useful in the diagnosis of nonhereditary pancreatic conditions: arguments for the motion.
    Whitcomb DC
    Can J Gastroenterol; 2003 Jan; 17(1):47-52. PubMed ID: 12560855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characteristics and Clinical Outcomes of Individuals at High Risk for Pancreatic Cancer: A Descriptive Analysis from a Comprehensive Cancer Center.
    McNamara GPJ; Ali KN; Vyas S; Huynh T; Nyland M; Almanza D; Laronga C; Klapman J; Permuth JB
    Gastrointest Disord (Basel); 2019 Mar; 1(1):106-119. PubMed ID: 32601617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human cationic trypsinogen but not serine peptidase inhibitor, Kazal type 1 variants increase the risk of type 1 autoimmune pancreatitis.
    Chang MC; Jan IS; Liang PC; Jeng YM; Yang CY; Tien YW; Wong JM; Chang YT
    J Gastroenterol Hepatol; 2014 Dec; 29(12):2038-42. PubMed ID: 24909264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutations in serine protease inhibitor Kazal type 1 are strongly associated with chronic pancreatitis.
    Drenth JP; te Morsche R; Jansen JB
    Gut; 2002 May; 50(5):687-92. PubMed ID: 11950817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atypical familial presentation of FAMMM syndrome with a high incidence of pancreatic cancer: case finding of asymptomatic individuals by EUS surveillance.
    Kluijt I; Cats A; Fockens P; Nio Y; Gouma DJ; Bruno MJ
    J Clin Gastroenterol; 2009 Oct; 43(9):853-7. PubMed ID: 19417680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pancreatic cancer screening in a prospective cohort of high-risk patients: a comprehensive strategy of imaging and genetics.
    Verna EC; Hwang C; Stevens PD; Rotterdam H; Stavropoulos SN; Sy CD; Prince MA; Chung WK; Fine RL; Chabot JA; Frucht H
    Clin Cancer Res; 2010 Oct; 16(20):5028-37. PubMed ID: 20876795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors of pancreatic cancer and their possible uses in diagnostics.
    Lang J; Kunovský L; Kala Z; Trna J
    Neoplasma; 2021 Mar; 68(2):227-239. PubMed ID: 33350848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.